Compare USAU & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAU | CGEN |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.1M | 201.8M |
| IPO Year | 2020 | 2001 |
| Metric | USAU | CGEN |
|---|---|---|
| Price | $8.40 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $26.50 | $4.80 |
| AVG Volume (30 Days) | 153.1K | ★ 193.0K |
| Earning Date | 12-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,402,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $55.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.55 | $1.43 |
| 52 Week High | $23.72 | $3.24 |
| Indicator | USAU | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 27.43 | 37.41 |
| Support Level | N/A | $1.87 |
| Resistance Level | $16.65 | $2.18 |
| Average True Range (ATR) | 0.69 | 0.09 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 1.26 | 12.87 |
U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.